The Journal of Practical Medicine ›› 2021, Vol. 37 ›› Issue (11): 1461-1465.doi: 10.3969/j.issn.1006⁃5725.2021.11.018

• Drugs and Clinic Practice • Previous Articles     Next Articles

R541.9 Clinical analysis of Sacubitril ⁃ Valsartan in patients with clinical diastolic heart failure 

PENG Jin， ZHANG Binyue，DAI Huiyong，CAO Jia，MAO Liang，ZHU Lingling，YAO Xianping，ZHANG Yuanyuan. *   

  1. De-partment of Cardiology，the 928th Hospital of the Joint Logistic Support Force of the Chinese People′ s Liberation Army，Haikou 571159，China 

  • Online:2021-06-10 Published:2021-06-10
  • Contact: Zhang Yuanyuan E⁃mail：yzhang143@bwh.harvard.edu

Abstract:

Objective To observe and analyze the effectiveness and safety of sacubitril⁃valsartan for dia⁃ stolic heart failure. Methods A total of 113 participants confirmed with diastolic heart failure and ejection fraction of 50% or more from the cardiovascular department of the 928th Hospital of the Chinese People′s Liberation Army and the First Affiliated Hospital of Hainan Medical University from June，2019 to June，2020，were selected and randomly assigned to control group（n = 57）andexperimental observation group（n = 56）. The control group received conventional anti ⁃ heart failure therapy. The treatment plan of the observation group replaced the ARB/ ACEI with sacubitril⁃valsartan instead. During the 6 month of observation and regular follow⁃up，we collected the baseline characteristics and clinical information before the research and analyzed the levels of blood pressure ， 6⁃min walking test（6MW）results，serum N⁃terminal pro⁃brain natriuretic peptide（NT⁃proBNP），AST，ALT， SCr，and potassium levels of the two groups. Meanwhile，cardiac ultrasonography related index of the two groups were tested and analyzed. Additionally，readmission rate，MACE and adverse reactions rate of the two groups were collected and compared. Results The clinical effective rate of the observation group was significantly higher than that of the control group. Greater reductions from baseline were found in patients who received sacubitril⁃ valsartan，including 6MW，NT⁃proBNP，LVEDVI，LVESVI，and mitral E/e′ ratio. The effectiveness of the drugs and the protection of the kidneys in the experimental group were also better than those in the control group. Readmission rate and adverse reactions rate were decreased in the experimental group. However，there were no statis⁃ tically differences in the blood pressure，liver function，serum potassium，EF%，LAVI levels and MACE between the two groups. Conclusions Sacubitril ⁃ Valsartan was effective and safe in the treatment of. clinical diastolic heart failure. 

Key words:

sacubitril?Valsartan, diastolic heart failure, NT?proBNP, mitral E/e′ ratio, drug effi? cacy evaluation